ibi310
MSI-H
Peking Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the MSI-H cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LENVATINIB Peking University | Phase 2 | CCC |
Tirelizumab Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
Cyclophosphamide Evelo Biosciences, Inc. | Phase 1 | CC |
Pembrolizumab Evelo Biosciences, Inc. | Phase 1 | CC |
Epirubicin Evelo Biosciences, Inc. | Phase 1 | CC |
edp1503 Evelo Biosciences, Inc. | Phase 1 | CC |
Sotigalimab Apexigen America, Inc. | Phase 1 | CC |
Same molecule, other indications
ibi310 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →